2023 Fiscal Year Research-status Report
Creation of a lymphatic drug delivery system: controlling distant metastasis and immune-related adverse events
| Project/Area Number |
22K18203
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2022-04-01 – 2025-03-31
|
| Keywords | lymph node metastasis / checkpoint inhibitor / chemoimmunotherapy |
|---|
| Outline of Annual Research Achievements |
Immunotherapy using immune checkpoint inhibitors (ICIs) is revolutionizing cancer metastasis treatment. However, few head and neck cancer (HNC) patients respond to ICIs with a high incidence of immune-related Adverse Events (irAEs). Still, a majority of them fail to respond. We created experimental mouse model by injecting luciferase expressing tumor cells and ICIs were injected as mono- or sequentially with combination of docetaxel. Treatment effects were evaluated over time, and final confirmation was made histologically along with irAEs. We found more significant tumor inhibition in the chemo-immunotherapy groups than in mono-immunotherapy.
|
| Current Status of Research Progress |
Current Status of Research Progress
2: Research has progressed on the whole more than it was originally planned.
Reason
At this moment, we have completed ICI effects on metastatic LN mouse model as a monotherapy or chemoimmunotherapy. We observed inhibition of tumor progression in the lymphatic drug delivery system delivered mono-ICI with he reduced irAEs. The chemoimmunotherapy group investigation is still on going as planned
|
| Strategy for Future Research Activity |
We plan to finish effect of chemoimmunotherapy for metastatic LN mouse model. Therefore, planning to broaden the effect of ICIs or chemoimmunotherapy for LN resected mouse model.
|
| Causes of Carryover |
The unused amount generated by the efficient promotion of research in the current fiscal year will be used in the next fiscal year (FY). This
amount, together with the amount requested for FY2024, will be used to carry out research in FY2024.
|
